Dong-A ST said Monday that it has confirmed that Zydena (ingredient: Udenafil), its erectile dysfunction treatment, improves postmicturition dribbling (PMD).
|Dong-A ST's erectile dysfunction treatment Zydena|
PMD is a common symptom in middle-aged men where men experience an involuntary loss of urine immediately after they have finished passing urine. The symptom is due to the weakening of the urethral muscles, which in turn leaves behind urine in the urethra, or the bladder not shrinking sufficiently when it releases a small amount of urine.
The company conducted the study to confirm the efficacy of Udenafil on male patients suffering from PMD by dividing 138 patients into two groups and either prescribing Zydena 75 mg or giving placebo for 12 weeks.
Afterward, the company conducted a follow-up study for 18 months from December 2014 to May 2016 at four medical institutions.
Of the 138 patients who participated in the study, 59 experienced PMD symptoms one out of three bathroom visits, 45 had PMD symptoms two out of three bathroom visits, and 34 said they experienced PMD symptoms every time they went to the bathroom.
Also, 89 patients pointed out that PMD causes normal or severe discomfort in daily life.
As a result of the trial, the company confirmed that the group treated with Zydena showed significant improvement, such as reduced PMD symptoms compared to the placebo group.
“The study confirmed that Zydena could be an effective treatment for PMD,” a company official said. “We will continue to obtain data on efficacy and safety for patients suffering from PMD.”
<© Korea Biomedical Review, All rights reserved.>